Aditxt

Aditxt Capital Expenditures

The Capital Expenditures (CapEx) of Aditxt (ADTX) as of Oct 28, 2026 is -13.74 M USD. In the previous year, Capital Expenditures (CapEx) was -1.00 USD — a change of 1.37 B% (lower).

Capital Expenditures

-13.74 MUSD

YoY

1.37 B%

Last updated:

Capital Expenditures (CapEx) of Aditxt is 2025 -13.74 M USD. Capital Expenditures (CapEx) of Aditxt was 2024 -1.00 USD. It decreases by 1.37 B% lower compared to the previous year.

The Aditxt Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-170,629.00 USD
Jan 1, 2019
-170,629.00 USD
Jan 1, 2020
-170,629.00 USD
Jan 1, 2021
-1.02 M USD
Jan 1, 2022
-367,079.00 USD
Jan 1, 2023
-14,407.00 USD
Jan 1, 2024
-1.00 USD
Jan 1, 2025
-13.74 M USD
The Aditxt Capital Expenditures history
YEARCapital ExpendituresYoY
-13.74 MUSD+1.37 B%
-1.00USD-99.99%
-14,407.00USD-96.08%
-367,079.00USD-63.86%
-1.02 MUSD+495.30%
-170,629.00USD0.00%
-170,629.00USD0.00%
-170,629.00USD0.00%
-170,629.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aditxt Stock analysis

What does Aditxt do? ADiTx Therapeutics, Inc. develops nucleic acid-based technologies for organ transplant tolerance and immune system health. The company's Apoptotic DNA Immunotherapy (ADi) reprograms the immune system to induce tolerance, while Aditxt Immune Monitor (AiM) provides personalized immune profiles. Both technologies are in preclinical development, with the firm focusing on minimizing transplant rejection and addressing autoimmune diseases and allergies. The company is headquartered in Mountain View, California and employs 2 full-time staff. ADiTx Therapeutics, Inc. generates revenue through the development and potential future commercialization of its immune reprogramming and monitoring technologies. The company is a preclinical stage life sciences entity targeting medical applications in organ transplantation and immune-related conditions. Its core products, ADi and AiM, are designed to address unmet medical needs in immune system management. The firm's focus on immune reprogramming and monitoring positions it for potential partnerships with healthcare providers and biopharmaceutical companies in the future. Aditxt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aditxt stock

Capital Expenditures (CapEx) of Aditxt is -13.74 M USD in 2025.

Capital Expenditures (CapEx) of Aditxt changed from -1.00 USD to -13.74 M USD, representing a 1.37 B% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Aditxt since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Aditxt historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Aditxt

All Key Metrics — Aditxt